Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Treatment with lovastatin reduced the risk of coronary events. Both the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) and the West of Scotland Coronary Prevention Study demonstrated that inhibitors of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase (statins) reduce...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2001-06, Vol.344 (26), p.1959-1965
Hauptverfasser:	Ridker, Paul M, Rifai, Nader, Clearfield, Michael, Downs, John R, Weis, Stephen E, Miles, J. Shawn, Gotto, Antonio M
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Anticholesteremic Agents - pharmacology Anticholesteremic Agents - therapeutic use Biological and medical sciences C-Reactive Protein - analysis Cardiology. Vascular system Cardiovascular disease Cholesterol Cholesterol - blood Cholesterol, HDL - blood Coronary Disease - blood Coronary Disease - prevention & control Coronary heart disease Double-Blind Method Follow-Up Studies Heart Heart attacks Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Lovastatin - pharmacology Lovastatin - therapeutic use Medical sciences Primary Prevention Proportional Hazards Models Proteins Risk Risk Factors Statins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!